Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)‘s stock had its “outperform” rating reaffirmed by equities researchers at Leerink Swann in a research note issued on Monday. They presently have a $90.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $94.00. Leerink Swann’s price target would suggest a potential upside of 10.52% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Jefferies Group set a $109.00 target price on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Sunday, September 18th. Credit Suisse Group AG restated a “buy” rating and issued a $101.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 9th. Canaccord Genuity set a $103.00 target price on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Friday, November 11th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $69.00 target price on the stock in a research report on Thursday, October 20th. Finally, Piper Jaffray Cos. set a $82.00 target price on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $94.23.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 81.43 on Monday. Ultragenyx Pharmaceutical has a 12 month low of $46.52 and a 12 month high of $117.12. The company’s market cap is $3.33 billion. The firm’s 50 day moving average is $66.94 and its 200 day moving average is $63.82.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.53) by $0.11. During the same quarter last year, the company earned ($1.03) EPS. On average, equities analysts predict that Ultragenyx Pharmaceutical will post ($6.14) earnings per share for the current year.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, October 14th. The shares were sold at an average price of $63.02, for a total value of $1,260,400.00. Following the completion of the sale, the chief executive officer now directly owns 480,632 shares of the company’s stock, valued at $30,289,428.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Shalini Sharp sold 12,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $61.40, for a total transaction of $736,800.00. Following the completion of the sale, the chief financial officer now directly owns 57,387 shares of the company’s stock, valued at $3,523,561.80. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Ultragenyx Pharmaceutical by 72.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,426 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 600 shares during the period. Pacer Advisors Inc. bought a new stake in Ultragenyx Pharmaceutical during the second quarter valued at $100,000. First Mercantile Trust Co. increased its stake in Ultragenyx Pharmaceutical by 1.7% in the third quarter. First Mercantile Trust Co. now owns 2,339 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 39 shares during the period. Springbok Capital Management LLC bought a new stake in Ultragenyx Pharmaceutical during the first quarter valued at $189,000. Finally, Prudential Financial Inc. bought a new stake in Ultragenyx Pharmaceutical during the third quarter valued at $245,000. 93.01% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.